Fremanezumab (INN), marketed under the trade name Ajovy, is a humanized monoclonal antibody directed against calcitonin-related polypeptides (CGRP) alpha and beta. It is used for the preventative treatment of migraine. Fremanezumab was discovered and developed by Rinat Neuroscience, was acquired by Pfizer in 2006, and was then licensed to Teva.
In 2018 Teva stopped development of fremanezumab for the treatment of chronic cluster headache after the primary endpoint of a Phase III trial was not met; Teva was still developing it for episodic cluster headache and migraine.
Other antibodies blocking the CGRP pathway:
- "International Nonproprietary Names for Pharmaceutical Substances (INN)" (PDF). WHO Drug Information. WHO. 31 (1). 2017.
- "Fremanezumab - Teva Pharmaceutical".
- "Teva Pulls Out of Chronic Cluster Headache Trial of Fremanezumab". MD Magazine. Retrieved 2018-06-19.
- "Teva Announces U.S. Approval of AJOVY™ (fremanezumab-vfrm) Injection, the First and Only Anti-CGRP Treatment with Both Quarterly and Monthly Dosing for the Preventive Treatment of Migraine in Adults". Teva Pharmaceutical Industries Ltd Pharmaceutical Industries Ltd. Teva Pharmaceutical Industries Ltd Pharmaceutical Industries Ltd. Retrieved 7 October 2018.
|This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.|
|This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.|